Evidence map›Paper›PMID 35347700›Full record

ArticleThe British journal of dermatology2022

Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3).

Veronica Di Carlo, Charles A Stiller, Nora Eisemann, Andrea Bordoni, Melissa Matz, Maria P Curado, Laetitia Daubisse-Marliac, Mikhail Valkov, Jean-Luc Bulliard, David Morrison and 9 more

Abstract read
In one paragraph

Article in The British journal of dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Adjuvant Therapy in Acral Melanoma: A Systematic Review.Clinical, cosmetic and investigational dermatology · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Veronica Di CarloCancer Survival Group, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK.ORCID 0000-0001-7244-9526
Charles A StillerNational Disease Registration Service, NHS Digital, London, UK.
Nora EisemannInstitute of Social Medicine and Epidemiology, University of Lübeck, Ratzeburger Allee, 160 23538, Lübeck, Germany.
Andrea BordoniTicino Cancer Registry, Dipartimento Sanità e Socialità, Divisione della Salute Pubblica, Via Ciseri, 10 6600, Locarno, Switzerland.
Melissa MatzCancer Survival Group, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK.
Maria P CuradoGoiânia Cancer Registry, Group of Epidemiology and Statistics on Cancer, AC Camargo Cancer Center, Rua Tamandaré 753 - Liberdade, SP, 01525-001, São Paulo, Brazil.
Laetitia Daubisse-MarliacTarn Cancer Registry, Institut Universitaire du Cancer Toulouse - Oncopole Institut C. Regaud, 1 Avenue Irène Joliot-Curie, 31059, Toulouse, France.
Mikhail ValkovNorthern State Medical University, Prospekt Troitskiy, 51 163000, Arkhangelsk, Russian Federation.
Jean-Luc BulliardCentre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
David MorrisonScottish Cancer Registry, Gyle Square, 1 South Gyle Crescent, EH12 9EB, Edinburgh, UK.
Chris JohnsonCancer Data Registry of Idaho, 615 North 7th Street, ID, 83701-1278, Boise, USA.
Fabio GirardiCancer Survival Group, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK.
Rafael Marcos-GrageraEpidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology (ICO), IDIBGI, Oncology Coordination Plan, Department of Health Government of Catalonia, 17004, Girona, Spain.
Mario ŠekerijaCroatian National Cancer Registry, Croatian Institute of Public Health, Rockefeller Street, 7 10000, Zagreb, Croatia.
Siri LarønningenCancer Registry of Norway, Ullernchausseen, 64 0379, Oslo, Norway.
Eunice SirriEpidemiological Cancer Registry of Lower Saxony, Offis Caree GmbH, Industriestr, 92 6121, Oldenburg, Germany.
Michel P ColemanCancer Survival Group, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK.
Claudia AllemaniCancer Survival Group, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, UK.
CONCORD Working Group

Funding

American Cancer SocietyCDC HHSInstitut National Du CancerLigue Contre le CancerNCI NIH HHSRossy Family FoundationSusan G. KomenSwiss Cancer LeagueSwiss Cancer Research FoundationSwiss Re
6 · The paper itself

Abstract

backgroundCONCORD-3 highlighted wide disparities in population-based 5-year net survival for cutaneous melanoma during 2000-2014. Clinical evidence suggests marked international differences in the proportion of lethal acral and nodular subtypes of cutaneous melanoma.

objectivesWe aimed to assess whether the differences in morphology may explain global variation in survival.

methodsPatients with melanoma were grouped into the following seven morphological categories: malignant melanoma, not otherwise specified (International Classification of Diseases for Oncology, third revision morphology code 8720), superficial spreading melanoma (8743), lentigo maligna melanoma (8742), nodular melanoma (8721), acral lentiginous melanoma (8744), desmoplastic melanoma (8745) and other morphologies (8722-8723, 8726-8727, 8730, 8740-8741, 8746, 8761, 8770-8774, 8780). We estimated net survival using the nonparametric Pohar Perme estimator, correcting for background mortality by single year of age, sex and calendar year in each country or region. All-ages survival estimates were standardized using the International Cancer Survival Standard weights. We fitted a flexible parametric model to estimate the effect of morphology on the hazard of death.

resultsWorldwide, the proportion of nodular melanoma ranged between 7% and 13%. Acral lentiginous melanoma accounted for less than 2% of all registrations but was more common in Asia (6%) and Central and South America (7%). Overall, 36% of tumours were classified as superficial spreading melanoma. During 2010-2014, age-standardized 5-year net survival for superficial spreading melanoma was 95% or higher in Oceania, North America and most European countries, but was only 71% in Taiwan. Survival for acral lentiginous melanoma ranged between 66% and 95%. Nodular melanoma had the poorest prognosis in all countries. The multivariable analysis of data from registries with complete information on stage and morphology found that sex, age and stage at diagnosis only partially explain the higher risk of death for nodular and acral lentiginous subtypes.

conclusionsThis study provides the broadest picture of distribution and population-based survival trends for the main morphological subtypes of cutaneous melanoma in 59 countries. The poorer prognosis for nodular and acral lentiginous melanomas, more frequent in Asia and Latin America, suggests the need for health policies aimed at specific populations to improve awareness, early diagnosis and access to treatment. What is already known about this topic? The histopathological features of cutaneous melanoma vary markedly worldwide. The proportion of melanomas with the more aggressive acral lentiginous or nodular histological subtypes is higher in populations with predominantly dark skin than in populations with predominantly fair skin. What does this study add? We aimed to assess the extent to which these differences in morphology may explain international variation in survival when all histological subtypes are combined. This study provides, for the first time, international comparisons of population-based survival at 5 years for the main histological subtypes of melanoma for over 1.5 million adults diagnosed during 2000-2014. This study highlights the less favourable distribution of histological subtypes in Asia and Central and South America, and the poorer prognosis for nodular and acral lentiginous melanomas. We found that later stage at diagnosis does not fully explain the higher excess risk of death for nodular and acral lentiginous melanoma compared with superficial spreading melanoma.

Indexed as

Hutchinson's Melanotic FreckleMelanomaSkin NeoplasmsAdultCutaneous Malignant MelanomaHumansTaiwan

Identifiers

PMID35347700
PMCPMC9542891

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.